Sidra Medicine conducts first clinical trial for pediatric congenital hyperinsulinism

Doha, Qatar: Sidra Medicine, a member of Qatar Foundation, has successfully conducted Qatar s first industry sponsored pharmaceutical trial for pediat...

Doha, Qatar: Sidra Medicine, a member of Qatar Foundation, has successfully conducted Qatar's first industry-sponsored pharmaceutical trial for pediatric congenital hyperinsulinism on a young patient.

The trial follows Sidra Medicines launch of its Clinical Trials Program, aimed at offering a new lease of hope to children with rare and complex diseases. It primarily focuses on clinical trials that will benefit children in the Arab region, particularly those with rare diseases that lack effective treatment.

Sidra Medicine was selected as one of 22 leading centers worldwide to participate in the sunRIZE Phase 3 clinical trial.

Led by Rezolute, a biopharmaceutical company specializing in rare diseases, the trial underscores Sidra Medicines growing prominence in pediatric endocrinology and its commitment to advancing innovative, patient-centered care.

Congenital hyperinsulinism is a complex condition that causes life-threatening hypoglycemia in children due to excessive insulin production. Many patients are unresponsive to existing therapies and often require invasive pancreatic surgery, which can lead to lifelong complications such as diabetes and pancreatic insufficiency.